Recombinant therapeutic antibodies

Applied Microbiology and Biotechnology

Volumn 74, Issue 4, 2007, Pages 723-729

  Dübel, Stefan ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY THERAPEUTICS; RECOMBINANT ANTIBODIES;

BIOTECHNOLOGY; DISEASE CONTROL; DRUG PRODUCTS; MICROBIOLOGY;

ANTIBODIES;

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CETUXIMAB; CHIMERIC ANTIBODY; COTARA; DACLIZUMAB; EDRECOLOMAB; EFALIZUMAB; FANOLESOMAB TC 99M; GEMTUZUMAB OZOGAMICIN; HUMASPECT TC; IBRITUMOMAB TIUXETAN; IGOVOMAB; IMCIROMAB PENTATE; INDIMACIS; INFLIXIMAB; LEUKOSITE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MYOSIN ANTIBODY IN 111; NATALIZUMAB; OKT 3; OMALIZUMAB; ONCORAD; ONCOSCINT; ORTHOCLONE; PALIVIZUMAB; POLYCLONAL ANTIBODY; RANIBIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; SULESOMAB; SULESOMAB TC 99M; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECTIBIX; VERLUMA; VOTUMUMAB;

ANTIBODY; FUTURE PROSPECT; RECOMBINATION; TECHNOLOGICAL DEVELOPMENT;

AMINO ACID SEQUENCE; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ANTIGEN BINDING; ASTHMA; BREAST CANCER; COLON CANCER; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; GENETIC ENGINEERING; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYBRIDOMA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN STRUCTURE; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; MULTIPLE SCLEROSIS; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHAGE DISPLAY; PROTEIN DOMAIN; PSORIASIS; RHEUMATOID ARTHRITIS; SARCOMA; SHORT SURVEY; UTERUS CANCER; WEGENER GRANULOMATOSIS;

ANTIBODIES; BIOTECHNOLOGY; RECOMBINANT PROTEINS;

EID: 33847245397     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-006-0810-y     Document Type: Short Survey

References (24)

1. Bagshawe KD, Sharma SK, Begent RH (2004) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4:1777-1778
2. Boder ET, Katarina S, Midelfort, Dane Wittrup K (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97:10701-10705
3. Buelow R, Puels J, Hansen-Wester I, Thorey I, Schueler N, Siewe B, Niersbach H., van Schooten W, Platzer J (2006) Expression of a human antibody repertoire in transgenic rabbits. Hum Antib 15:19-23
4. Breitling F, Dübel S (1999) Recombinant antibodies. Wiley, New York, ISBN: 0-471-17847-0 (overview of the basic technologies and applications)
5. Bregenholt S, Haurum J (2004) Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin Biol Ther 4:387-396
6. Brüggemann M, Taussig MJ (1997) Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol 8:455-458
7. Dübel S (ed) (2007) Handbook of therapeutic antibodies. Wiley, ISBN 3-527-31453-9 (three volume reference from basic technologies to approved drugs)
8. Glassy MC, McKnight ME (2005) Requirements for human antibody cocktails for oncology. Expert Opin Biol Ther 5:1333-1338
9. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105-1116
10. Hosse R, Rothe A, Power BE (2006) A new generation of protein scaffolds for molecular recognition. Protein Sci 17:14-27
11. Hudson PJ (1999) Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 11:548-557
12. Hust M, Dübel S (2004) Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol 295:71-95
13. Jefferis R (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21:1116-1121
14. Kontermann RE (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26:1-9
15. Kontermann R, Dübel S (eds) (2001) Antibody engineering. Springer, Berlin Heidelberg New York, ISBN: 3-540-41354-5 (collection of relevant protocols)
16. Monoclonal Antibodies and Therapies (multiple authors). Supplement of Nature Biotech, Nov. 2004 (collection of reviews)
17. Newton DL, Rybak SM (2001) Preparation and preclinical characterization of RNase-based immunofusion proteins. Methods Mol Biol 160:387-406
18. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K (2005) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306:151-160
19. Nygren PA, Skerra A (2004) Binding proteins from alternative scaffolds. J Immunol Methods 290:3-28
20. Rohrbach P, Broders O, Toleikis L, Dübel S (2003) Therapeutic antibodies and antibody fusion proteins. Biotechnol Genet Eng Rev 20:129-155
21. Taussig MJ, Stoevesandt O, Borrebaeck C, Bradbury A, Dübel S, Frank R, Gibson T, Gold L, Herberg F, Hermjakob H, Hoheisel J, Joos T, Konthur Z, Landegren U, Plückthun A, Ueffing M, Uhlén M (2007) ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods, in press, Jan. 2007
22. Toleikis L, Broders O, Dübel S (2004) Cloning single chain antibody fragments (scFv) from hybridoma clones. In: Decker J, Reischl U (eds) Molecular diagnosis of infectious diseases, 2nd edn. Humana Press, Totowa, NJ, pp 447-458
23. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147-59
24. Weintraub JA, Hilton JF, White JM, Hoover CI, Wycoff KL, Yu L, Larrick JW, Featherstone JDB (2005) Clinical trial of a plant-derived antibody on recolonization of mutans streptococci. Caries Res 39:241-250